Company / Shareholders' Equity
Trevi Therapeutics, Inc. Shareholders' Equity History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$99.6M
FY2024
5-year range
$17.1M / $107.5M
FY2020-FY2024
Trend
+20.7%
vs FY2023
Sector context
#171 of 213
Health Care
What the data says
Trevi Therapeutics, Inc.'s shareholders' equity of $100M is lower than 80% of companies in the Health Care sector (FY2024). Shareholders' Equity has fluctuated over the past 7 years, ranging from -$109M in FY2018 to $107M in FY2022.
Based on SEC 10-K filings.
$100M in FY2024 with a 5-year CAGR of +12.8%.
Declined from $107M to $100M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +80.0%
- 5-Year CAGR
- +12.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 213This company $99.6M Sector average $2.5B
▼
-96.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +12.8%, indicating consistent growth.
- In FY2024, shareholders' equity increased 20.7% year-over-year.
- Ranks #171 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.91 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $99.6M | +20.7% |
| FY2023 | $82.5M | -23.2% |
| FY2022 | $107.5M | +529.3% |
| FY2021 | $17.1M | -37.4% |
| FY2020 | $27.3M | -50.0% |
| FY2019 | $54.5M | +149.8% |
| FY2018 | -$109.5M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026